Investors

Manus Neurodynamica is backed by Par Equity, angel investors with a focus on high growth; Scottish Investment Bank, the investment arm of Scotland’s main economic development agency; Old College Capital, the venture capital arm of The University of Edinburgh; and individual investors including members of the board.

Together these investors provided seed capital in a funding round in 2018.

par-equity

Par Equity

Par Equity is a venture capital investor focused on businesses with global ambitions, and innovative technology at their core. Since 2009 it has made 40 investments in a wide variety of growth companies and has achieved a number of profitable exits.

Par Equity’s model integrates the insights and experiences of industry insiders into every facet of the investment process and, because these people are investors, their interests are closely aligned with Par Equity’s managed venture funds. The investor network also provides a pool of individuals who can work with entrepreneurs to help them overcome the challenges that are frequently encountered in building high-growth companies.

www.parequity.com

old-college-captial

Old College Capital

Old College Capital LP (OCC) is the in house venture capital fund of the University of Edinburgh. The Fund was established in 2011 with support from the University and its Endowment Fund. The objective of the Fund is to provide growth and development finance into early and mid-stage spin-out and start-up companies as part of syndicated venture capital rounds.

OCC follows a formal investment process and the Investment Committee makes the decision for OCC to invest or not. The Committee has highly experienced and respected individuals drawn from the University and the financial services industry.

www.oldcollegecapital.com

scottish-investment-bank

Scottish Investment Bank

The Scottish Investment Bank (SIB) is the investment arm of Scottish Enterprise working in partnership with Highlands and Islands Enterprise.

SIB supports economic growth by increasing the supply of finance to Scottish businesses, and helping companies to identify appropriate sources of finance, engage with funders and secure the investment they need to grow their business, as well as helping them strengthen their management teams, make connections and accelerate growth.

SIB operates a number of equity funds on a shared risk co-investment basis with UK and international investors, including business angels, angel syndicates, venture capital groups and corporate investors.

Where equity investment is provided Scottish Enterprise becomes a shareholder in the business.

www.scottish-enterprise.com/sib

Craig L. Burr

Mr. Craig L. Burr serves as an Advisor at Woodhaven Capital Partners. He is Limited Partner at J. Devien Capital, LLC, Johns Creek Partners, LLC, The Zucker Group, Channelstone Capital Partners, LLC, Longreach Capital, LLC and Blue Horizon Capital, LLC. Mr. Burr is employed at Blackford Capital, LLC. Mr. Burr served as an Advisor at Agilis Equity Partners LLC. He was the Founder and Managing Director at Burr, Egan, Deleage & Co. He founded the Burr, Egan, Deleage & Co in 1979. Mr. Burr served as a Partner at TA Associates. Previously, he was employed at Bartley Capital, LLC. He served as Director of NuCO2 Florida Inc. since May 1999 until November 2004. He served as a Member of Advisory Board of Pod Investment AB. He serves as a Member of the Board of Directors of the New England Venture Capital Association. Mr. Burr holds an M.B.A. degree from Harvard Business School and a A.B. degree, cum laude, from the Harvard College.

Investment enquiry

We would welcome opportunities to discuss our business plan with potential investors.

Partners & Collaborators

smartpoints-greyscale
Partner logo cambridge cognition
Partner logo VTT
Partner logo Northumbria Healthcare
Partner logo Par Equity
Partner logo SBRI
Partner logo Stabilo
Partner logo UMCG

Make a difference today

Our disruptive technology has the potential to be used across many applications such as screening and triage, diagnosis, drug treatment optimisation, drug development, rehabilitation and research to improve our understanding of neuromotor impairments. We are keen to continue collaborating with interested researchers, clinicians and practitioners on our research in different areas, as well as businesses for further development and rolling out the existing and new products worldwide.